Apollo Hospitals has told investors it plans to add more than 5,800 beds over the next five years. At a share price near ₹7,895, the question is simple: will those beds earn enough money to move the stock by 2030?
This guide looks at the latest quarter, how busy the hospitals are, and what today’s price would become under three different growth paths. The 2030 numbers are examples, not predictions.
Quick answer
No one can state the exact Apollo Hospitals share price for 2030. If we start from about ₹7,895 and assume 6%, 11% or 16% growth a year, the price would be near ₹9,970, ₹11,990 or ₹14,290 in 2030. These are practice sums, not forecasts.
Where the stock stands
| Item | Figure |
|---|---|
| Latest price we found (7 October 2026) | ₹7,895 |
| Previous close | ₹7,910 |
| 52-week range | ₹6,680 to ₹9,326.80 |
| Change over six months | about +5.75% |
The stock sits in the middle part of its yearly range. It is neither at a low nor near its high.
What the April–June 2026 results show
| Measure | Apr–Jun 2026 | A year earlier | Change |
|---|---|---|---|
| Revenue | about ₹7,043 crore | ₹5,842 crore | about +21% |
| Net profit (PAT) | about ₹581 crore | ₹433 crore | about +34% |
| EBITDA | ₹1,092 crore | — | about +28% |
| EBITDA margin | about 15.5% | about 14.6% | +0.9 points |
| Core hospital business revenue | ₹3,567 crore | — | about +22% |
| Bed occupancy | about 70% | — | — |
Profit numbers differ: some outlets show ₹597 crore or ₹610 crore for the same quarter. The ₹581 crore figure matches the company filing summary, so we use it. The other numbers may use a different definition, such as total profit. Always check the exchange filing.
Why beds matter for the share price
A hospital makes money when its beds are used. Occupancy of about 70% means roughly seven out of ten beds were filled on average. A new bed costs money to build and takes time to fill. That is why the 5,800-bed plan can lift revenue later but can also weigh on profit while the new wings are still ramping up.
Scenarios for 2030
The formula is simple: future price = starting price × (1 + yearly growth) ^ number of years. The growth rates below are examples picked to show a range. They are not analyst targets.
- Cautious (6% a year): new beds fill slowly and costs stay high.
- Steady (11% a year): beds are added on time and revenue and margins keep rising as they have this year.
- Strong (16% a year): occupancy rises, newer services such as oncology and cardiology grow fast, and the market pays more for the earnings.
| Year | Cautious (6% a year) | Steady (11% a year) | Strong (16% a year) |
|---|---|---|---|
| 2027 | ₹8,370 | ₹8,760 | ₹9,160 |
| 2028 | ₹8,870 | ₹9,730 | ₹10,620 |
| 2029 | ₹9,400 | ₹10,800 | ₹12,320 |
| 2030 | ₹9,970 | ₹11,990 | ₹14,290 |
What could help
- Higher occupancy in existing hospitals.
- Growth in high-value care such as cardiology, oncology and neurology.
- Steady margin improvement, as seen in the latest quarter.
What could hurt
- Building beds takes a lot of money and time; delays raise costs.
- Rules on treatment pricing or insurance payouts.
- Doctor and nurse shortages, which limit how fast new beds can be used.
- A high share price already reflects good news.
What ₹1,00,000 could become (example)
| Scenario | Yearly growth assumed | Value in 2030 | Gain |
|---|---|---|---|
| Cautious | 6% | ₹1,26,300 | +₹26,300 |
| Steady | 11% | ₹1,51,900 | +₹51,900 |
| Strong | 16% | ₹1,81,000 | +₹81,000 |
What to track every quarter
- Revenue and net profit compared with the same quarter last year.
- Operating margin (EBITDA margin) and whether it is rising or falling.
- Debt level and interest cost.
- Order book or new deals, if the company reports them.
- Promoter holding and any pledge of shares.
- Dividend and other corporate announcements on NSE and BSE.
Key terms in simple words
| Term | Meaning |
|---|---|
| EBITDA | Profit from operations before interest, tax and depreciation. |
| PAT | Profit after tax, the profit left for owners. |
| 52-week range | The lowest and highest price in the last year. |
| Compounding | Growth on growth: each year’s gain is added to the base for the next year. |
How we prepared this article
We collect numbers from company results, exchange filings where available and public news and price pages, and we note the date of each price. Where sources disagree, we say so instead of picking one quietly. Scenario tables use a simple formula and are examples, not predictions. We do not take payment to publish targets. Found a mistake? Tell us and we will correct it.
Frequently asked questions
What is the Apollo Hospitals share price target for 2030?
No one can give a fixed number. With a base of about ₹7,895 and growth of 6% to 16% a year, the example range for 2030 is ₹9,970 to ₹14,290.
Is the company name Apollo Hospital or Apollo Hospitals?
The listed company is Apollo Hospitals Enterprise Ltd, trading on NSE as APOLLOHOSP. People often search for it as “Apollo Hospital”.
How fast did Apollo grow in the latest quarter?
Revenue grew about 21% year on year to about ₹7,043 crore, and net profit rose about 34% to about ₹581 crore.
Is Apollo Hospitals good for the long term?
That depends on your goals and risk comfort, which we cannot judge for you. Read the filings, consider the risks above and speak to a SEBI-registered adviser.
How often is this article updated?
We review it after each quarterly result and when major company news arrives. The review date is shown at the bottom of the page.
Where can I check the live share price?
On the NSE and BSE websites or in your broker’s app. Prices on this page carry a date and may be delayed.
Are the scenarios an analyst target?
No. They are simple examples built from one formula and different growth rates. Real prices can be far above or below them.
Conclusion
Apollo Hospitals is growing revenue and profit and has a clear plan for more beds. What the share price will do by 2030 depends on how well it fills those beds and controls costs. Watch occupancy, margin and debt each quarter instead of leaning on one future number.
Related reading: Zensar share price target 2030, ITC share price target 2050.
Watch: a related video
Video by NDTV Profit: Why Apollo Hospitals Is Betting Big On India’s Healthcare Boom. This is a third-party video shown for learning only. Its views belong to the speaker, not to SharePriceHub, and are not investment advice.
Sources
- Kotak Neo: Apollo Hospitals Q1 FY27 results
- Indian Pharma Post: 21% revenue growth in Q1 FY27
- Multibagg: Q1 FY27 margin and EBITDA
- Investywise: Q1 FY27 filing summary
- Anand Rathi: Apollo Hospitals share price
- NSE India and BSE India
Price data as of 7 October 2026. Results data for the quarter ended 30 June 2026 unless stated. Last reviewed 13 October 2026.
Disclaimer: This article is for education only. Share prices and forecasts can change, and past performance does not guarantee future results. It is not personal investment advice, and SharePriceHub is not a SEBI-registered adviser. Please check current information on official sources and speak to a qualified financial adviser before you invest. Read the full disclaimer.
